In the next 10 years, 150+ drugs will come off patent protection. These drugs are worth over $100 Billion in sales.
Our Mission
Laxxon Medical is dedicated to engineering patented 3D pharmaceutical solutions which optimize products and benefit patients.
The basis of Laxxon's pharmaceutical solutions is our cutting-edge 3D screen printing technology and the extensive intellectual property surrounding it.
Our commitment to innovation and health is fueled by the expertise, integrity, agility, and diversity of the Laxxon team.
Laxxon strives to accelerate pharmaceutical progress globally by establishing ourselves as the leader in the field of 3D printed drugs.
Newsroom
Laxxon Medical Announces Development Program for Non-Invasive, 3D Printed Oral GLP-1 Asset, Offering an Alternative to GLP-1 Injections on Market
Laxxon Medical and Adare Pharma Solutions Announce Joint Cooperation for Production of cGMP 3D Printed Oral Dosage Forms in Europe and US
Newsroom
The cooperation between Laxxon and Adare enables the clinical and commercial production of advanced drug delivery systems at Adare’s cGMP facilities in Italy and US.
Laxxon Medical to Showcase LXM.2, Innovative Oral GLP-1 Agonist including Multi-Compartment Micro-Tablet Form at 2024 BIO-Europe Convention
Newsroom
Attending BIO-Europe? Laxxon is seeking out-licensing opportunities for lead asset LXM.2, or co-developments projects with 3DSP platform technology SPID®.
Laxxon Medical is a pharma-technology company pioneering a new generation of advanced pharmaceuticals with SPID®, a novel 3D screen printing platform technology.
For new and common pharmaceutical drugs, SPID® unlocks innovative drug delivery advancements paired with fast-tracked market access and extensive IP protection to yield disruptive opportunities for partners and life-changing results for patients.
Laxxon is the leader of 3D screen-printed additive manufacturing in in the pharmaceutical industry, globally.
Patent Extension
Advanced Patented Generics
New Drug Development
Our Solutions
Events
Laxxon has both an external pipeline and in-house Advanced Patented Generic pipeline.
03.